NovaBridge Secures FDA Alignment for Accelerated Approval Pathway of Givastomig in Gastric Cancer
NBP has more than doubled off its 52-week low of $0.595.
Summary
NovaBridge Biosciences announced FDA alignment for an accelerated approval pathway for its lead gastric cancer candidate, givastomig, paving the way for a registrational Phase 3 trial in Q4 2026.
Key Events · Product Development and Regulatory · NBP
-
FDA Alignment for Accelerated Approval
The FDA confirmed givastomig's potential eligibility for an accelerated approval pathway in first-line Her2-, CLDN 18.2+, PD-L1+ gastroesophageal cancer patients.
-
Registrational Phase 3 Trial Planned
NovaBridge expects to initiate a registrational Phase 3 combination trial as early as Q4 2026, using objective response rate (ORR) as a primary endpoint for accelerated approval.
-
Positive Phase 1b Data Underpins Decision
This regulatory milestone builds on robust efficacy and favorable tolerability observed in the Phase 1b combination trial, which showed a 75% objective response rate and 16.9-month median progression-free survival.
Analysis · NBP · Life Sciences
This 6-K reports a significant regulatory milestone for NovaBridge Biosciences, as the FDA has confirmed givastomig's potential eligibility for an accelerated approval pathway in first-line gastric cancer. This alignment, based on compelling Phase 1b data, de-risks the development process and could expedite market access for a potential first-in-class therapeutic. The company plans to initiate a registrational Phase 3 trial in Q4 2026, which is a critical step towards commercialization.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.9% of the 1009 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NBP was trading at $3.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $326.3M. The 52-week trading range was $0.60 to $6.79. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.